Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

  • There is currently no data for AGL

Angle News

TRADING UPDATES: Angle US lab boost; Corcel to capitalise on nickel
18 Mar 2022

TRADING UPDATES: Angle US lab boost; Corcel to capitalise on nickel

(Alliance News) - The following is a round-up of updates by London-listed companies, issued this week and not separately reported by Alliance News:

LONDON BROKER RATINGS: Jefferies cuts Berkeley, Barratt and Bellway
24 Jan 2022

LONDON BROKER RATINGS: Jefferies cuts Berkeley, Barratt and Bellway

LONDON BROKER RATINGS: Jefferies cuts Berkeley, Barratt and Bellway

Study shows potential for Angle's Parsortix system in clinical trials
21 Jan 2022

Study shows potential for Angle's Parsortix system in clinical trials

Study shows potential for Angle's Parsortix system in clinical trials

Angle says Parsortix system could replace cancer tissue biopsy
17 Jan 2022

Angle says Parsortix system could replace cancer tissue biopsy

Angle says Parsortix system could replace cancer tissue biopsy

Angle cancer study delayed as accreditation process for labs starts
13 Jan 2022

Angle cancer study delayed as accreditation process for labs starts

Angle cancer study delayed as accreditation process for labs starts

TRADING UPDATES: Harvest Minerals sales jump; Quartix earnings to rise
10 Jan 2022

TRADING UPDATES: Harvest Minerals sales jump; Quartix earnings to rise

TRADING UPDATES: Harvest Minerals sales jump; Quartix earnings to rise

EXECUTIVE CHANGES: Halma hires non-exec; Diurnal names new chair
15 Nov 2021

EXECUTIVE CHANGES: Halma hires non-exec; Diurnal names new chair

EXECUTIVE CHANGES: Halma hires non-exec; Diurnal names new chair

Angle first-half loss widens, crucial FDA decision expected this year
30 Sep 2021

Angle first-half loss widens, crucial FDA decision expected this year

Angle first-half loss widens, crucial FDA decision expected this year